Literature DB >> 10603936

Phospholamban ablation and compensatory responses in the mammalian heart.

G Chu1, D G Ferguson, I Edes, E Kiss, Y Sato, E G Kranias.   

Abstract

Phospholamban is a low molecular weight phosphoprotein in cardiac sarcoplasmic reticulum. The regulatory role of phospholamban in vivo has recently been elucidated by targeting the gene of this protein in embryonic stem cells and generating phospholamban-deficient mice. The phospholamban knockout hearts exhibited significantly enhanced contractile parameters and attenuated responses to beta-agonists. The hyperdynamic cardiac function of the phospholamban knockout mice was not accompanied by any cytoarchitectural abnormalities or alterations in the expression levels of the cardiac sarcoplasmic reticulum Ca(2+)-ATPase, calsequestrin, Na(+)-Ca2+ exchanger, or the contractile proteins. Furthermore, the attenuation of the cardiac responses to beta-agonists was not due to alterations in the phosphorylation levels of the other key cardiac phosphoproteins in the phospholamban knockout hearts. However, ablation of phospholamban was associated with down-regulation of the ryanodine receptor, which suggests that a cross-talk between cardiac sarcoplasmic reticulum Ca2+ uptake and Ca2+ release occurred in an attempt to maintain Ca2+ homeostasis in these hyperdynamic phospholamban knockout hearts.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10603936     DOI: 10.1111/j.1749-6632.1998.tb08256.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  11 in total

1.  A micropeptide encoded by a putative long noncoding RNA regulates muscle performance.

Authors:  Douglas M Anderson; Kelly M Anderson; Chi-Lun Chang; Catherine A Makarewich; Benjamin R Nelson; John R McAnally; Prasad Kasaragod; John M Shelton; Jen Liou; Rhonda Bassel-Duby; Eric N Olson
Journal:  Cell       Date:  2015-01-29       Impact factor: 41.582

2.  Phospholamban ablation rescues the enhanced propensity to arrhythmias of mice with CaMKII-constitutive phosphorylation of RyR2 at site S2814.

Authors:  G Mazzocchi; L Sommese; J Palomeque; J I Felice; M N Di Carlo; D Fainstein; P Gonzalez; P Contreras; D Skapura; M D McCauley; E C Lascano; J A Negroni; E G Kranias; X H T Wehrens; C A Valverde; A Mattiazzi
Journal:  J Physiol       Date:  2016-02-02       Impact factor: 5.182

3.  The human phospholamban Arg14-deletion mutant localizes to plasma membrane and interacts with the Na/K-ATPase.

Authors:  Kobra Haghighi; Tracy Pritchard; Julie Bossuyt; Jason R Waggoner; Qunying Yuan; Guo-Chang Fan; Hanna Osinska; Ahmad Anjak; Jack Rubinstein; Jeffrey Robbins; Donald M Bers; Evangelia G Kranias
Journal:  J Mol Cell Cardiol       Date:  2011-12-01       Impact factor: 5.000

4.  Influence of a constitutive increase in myofilament Ca(2+)-sensitivity on Ca(2+)-fluxes and contraction of mouse heart ventricular myocytes.

Authors:  Jose L Puglisi; Paul H Goldspink; Aldrin V Gomes; Megan S Utter; Donald M Bers; R John Solaro
Journal:  Arch Biochem Biophys       Date:  2014-01-27       Impact factor: 4.013

5.  Induced overexpression of phospholemman S68E mutant improves cardiac contractility and mortality after ischemia-reperfusion.

Authors:  JuFang Wang; Jianliang Song; Erhe Gao; Xue-Qian Zhang; Tongda Gu; Daohai Yu; Walter J Koch; Arthur M Feldman; Joseph Y Cheung
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-01-31       Impact factor: 4.733

6.  Phospholamban knockout breaks arrhythmogenic Ca²⁺ waves and suppresses catecholaminergic polymorphic ventricular tachycardia in mice.

Authors:  Yunlong Bai; Peter P Jones; Jiqing Guo; Xiaowei Zhong; Robert B Clark; Qiang Zhou; Ruiwu Wang; Alexander Vallmitjana; Raul Benitez; Leif Hove-Madsen; Lisa Semeniuk; Ang Guo; Long-Sheng Song; Henry J Duff; S R Wayne Chen
Journal:  Circ Res       Date:  2013-07-15       Impact factor: 17.367

7.  Long-term rescue of a familial hypertrophic cardiomyopathy caused by a mutation in the thin filament protein, tropomyosin, via modulation of a calcium cycling protein.

Authors:  Robert D Gaffin; James R Peña; Marco S L Alves; Fernando A L Dias; Shamim A K Chowdhury; Lynley S Heinrich; Paul H Goldspink; Evangelia G Kranias; David F Wieczorek; Beata M Wolska
Journal:  J Mol Cell Cardiol       Date:  2011-08-05       Impact factor: 5.000

8.  Neuronal nitric oxide synthase signaling within cardiac myocytes targets phospholamban.

Authors:  Honglan Wang; Mark J Kohr; Christopher J Traynham; Debra G Wheeler; Paul M L Janssen; Mark T Ziolo
Journal:  Am J Physiol Cell Physiol       Date:  2008-04-09       Impact factor: 4.249

9.  Cardiac-specific overexpression of sarcolipin in phospholamban null mice impairs myocyte function that is restored by phosphorylation.

Authors:  Anthony O Gramolini; Maria G Trivieri; Gavin Y Oudit; Thomas Kislinger; Wenping Li; Mikin M Patel; Andrew Emili; Evangelia G Kranias; Peter H Backx; David H Maclennan
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-06       Impact factor: 11.205

10.  Determinants of Ca2+ release restitution: Insights from genetically altered animals and mathematical modeling.

Authors:  Alejandra Cely-Ortiz; Juan I Felice; Leandro A Díaz-Zegarra; Carlos A Valverde; Marilén Federico; Julieta Palomeque; Xander H T Wehrens; Evangelia G Kranias; Ernesto A Aiello; Elena C Lascano; Jorge A Negroni; Alicia Mattiazzi
Journal:  J Gen Physiol       Date:  2020-11-02       Impact factor: 4.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.